CEL-SCI reports Multikine cuts death risk by half in target head & neck cancer patients; seeks accelerated approval

CEL SCI CORP

CEO Geert Kersten's employment extended to August 31, 2027.
Multikine shows 28.6% absolute 5-year overall survival benefit vs control (p=0.0015) in target population.
Hazard ratio 0.349; risk of death cut in half at 5 years in target patients.
>35% pre-surgery tumor reductions/downstages (p<0.01) with low PD-L1 expression.
Company plans conditional/accelerated approval worldwide without waiting for new trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.